https://www.selleckchem.com/
Results The continuous daily dosing regimen was predicted to result in the longest survival. TAD (24.5 months) and VAD (25.5 months) increased median overall survival as compared to a fixed dose schedule (19.9 and 21.5 months, respectively) and CAD (19.7 and 21.3 months, respectively), without markedly raising the risk of intolerable toxicities. Changes in neutrophil count and sVEGFR-3 were accurately forecasted in the majority of subjects (65%), based on biweekly blood sampling. Conclusions Dose-adjustments based on the pharmacodynamic biomarkers neutr
Like
Comment
Share
